Strategy and Business Model.
The Board of Directors of Mereo BioPharma recognises the importance of sound corporate governance and has decided to apply the Corporate Governance Code published by the Quoted Companies Alliance (the ”QCA Code”). The QCA Code sets out a standard of minimum best practice for small and midsize quoted companies. Please see the QCA 10 Principles of Corporate Governance page on this website.
Mereo is focused on the acquisition, development and commercialisation of innovative therapeutics designed to address significant unmet medical needs in rare and specialty disease areas, and improve patient quality of life.
Mereo seeks to selectively acquire clinical-stage product candidates from large pharma and biotech companies and develop them to key value inflection points, then generate value realisation through sale, licensing or commercialisation. Since launch in March 2015, Mereo has acquired three product candidates from Novartis and one product candidate from AstraZeneca.
The company will continue to leverage its innovative business model and resources, acquire and develop additional product candidates that address a range of rare and specialty diseases with significant unmet clinical needs, and become an innovative leader in the specialty biopharmaceutical sector.
Never miss an update from Mereo. Sign up for and select the type of alerts you would like to receive by email.Register for Email Alerts
Share Price Information
Mereo is a specialty biopharma company developing innovative medicines for patients. Find out about our share price and latest trades.View Share Price